Abeona Therapeutics Securities Fraud Investigation
Analysis based on 13 articles · First reported Aug 27, 2026 · Last updated Sep 03, 2026
The investigation and the underlying revenue recognition shortfall have negatively impacted Abeona's stock price, which fell nearly 15% on the disclosure. The ongoing investigation may lead to further volatility and potential legal liabilities for the company, affecting investor confidence in the near term.
Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (Nasdaq: ABEO) concerning potential securities fraud or other unlawful business practices by the company and certain officers and/or directors. The investigation follows Abeona's August 13, 2026 press release reporting Q2 2026 financial results and an update on commercial execution for ZEVASKYN (prademagene zamikeracel). Abeona disclosed that while five patients were treated with the one-time therapy, only four treatments were recognized for revenue, as one batch lacked the minimum number of sheets required for revenue recognition. Following this news, Abeona's stock price fell $1.12 per share, or 14.95%, to close at $6.35 per share on August 13, 2026. Pomerantz LLP, a prominent securities class action firm, is investigating whether Abeona and its management misled investors regarding the commercial performance of ZEVASKYN.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard